- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01775410
OptiCal COherence ToMography ABoard InformiNg AtherEctomy (COMBINE)
A Non-randomized, Multi-center Feasibility Trial of the Avinger Wolverine System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective, multi-center, non-randomized single arm feasibility trial of the Wolverine OCT guided atherectomy system. The trial is predominantly descriptive and, as such, not powered statistically although endpoint comparisons may be made to the published literature on peripheral atherectomy.
The trial will enroll up to 50 subjects diagnosed with peripheral vascular disease of the lower extremities. The primary disease must be located in reference vessel diameters ≥ 3.0 mm which is significant enough to cause moderate to severe symptoms and warrant vascular intervention. Trial success is focused on short term safety including rates of major adverse events. An evaluation of efficacy will also be performed and will include an evaluation of technical success defined as the percent of target lesions that has a residual diameter stenosis <50% post the Wolverine device alone as assessed by an independent review at the time of treatment using quantitative angiography or visual estimate.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Medellin, Colombia
- Clinical Cardiovascular
-
-
VAC
-
Cali, VAC, Colombia
- Angiografia de Occidente
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old.
- Patient is a candidate for percutaneous intervention for peripheral vascular disease in the legs.
- Patient is willing and able to give informed consent
- Documented symptomatic atherosclerotic peripheral vascular disease Rutherford Classification 2-5.
- Reference vessel lumen proximal to target lesion >2.5 mm in diameter by visual estimation.
- Subject has de novo target lesion(s) with stenosis >70% by visual estimation distal to the profunda femoral artery. No more than 2 lesions may be treated with the Wolverine device.
- Target lesion length <10 cm if target lesion >70% and <99% stenosed. If target lesion a chronic total occlusion (99-100% stenosed), target lesion length <4 cm.
- Patient is capable of meeting requirements and be present at the follow-up clinic visits at 30 days.
- At least one patent tibial run-off vessel at baseline.
Exclusion Criteria:
- Subject is pregnant or breast feeding.
- Rutherford Class 0 to 1 (asymptomatic and mild claudication).
- Rutherford Class 6 (critical limb ischemia).
- Severe calcification of the target lesion.
- Target lesion with any type of stent or graft.
- Target lesion in the iliac artery.
- Target lesion stenosis <70%.
- Subjects with significant (>70%) occlusive lesions proximal to the target lesion not successfully treated during the index procedure (upstream disease) and prior to treatment of the target lesion.
- Endovascular or surgical procedure performed on the index limb less than or equal to 30 days prior to the index procedure.
- Planned endovascular or surgical procedure 30 days after the index procedure.
- Lesion in the contralateral limb requiring intervention during the index procedure or within 30 days of the index procedure.
- Subjects with active infections whether they are being currently treated or not.
- Hemodialysis or GFR <30 mL/min or creatinine level >2.5mg/dL.
- Evidence or history of intracranial or gastrointestinal bleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2 months.
- Evidence or history of aneurysmal target vessel within the past 2 months.
- History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.
- Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
- Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is contraindicated.
- History of heparin-induced thrombocytopenia (HIT).
- Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 125,000/mm2 , known coagulopathy, or INR >1.5.
- Any thrombolytic therapy within 2 weeks of the index procedure.
- Any clinical and/or angiographic complication attributed to the use of another device prior to the insertion of the Wolverine into the subject.
- Subjects or their legal guardians who have not or will not sign the Informed Consent.
- Subjects who are unwilling or unable to comply with the follow-up study requirements.
- Participation in any study of an investigational device, medication, biologic or other agent within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Wolverine System
Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With no Major Adverse Events
Time Frame: Through 30 day follow-up
|
Freedom from major adverse events (MAE) through 30 day follow-up:
|
Through 30 day follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success: Percent of Target Lesions That Have a Residual Diameter Stenosis < 50%
Time Frame: During interventional procedure
|
Technical success is defined as the percent of target lesions that has a residual diameter stenosis < 50% post the Wolverine device alone as assessed by an independent review at the time of treatment using quantitative angiography or visual estimate
|
During interventional procedure
|
Procedural Success: Percent of Target Lesions That Have Residual Diameter Stenosis ≤30% Post-Wolverine and Any Other Adjunctive Therapy
Time Frame: Day 0
|
Day 0
|
|
Number of Participants With no Procedural Emboli
Time Frame: During interventional procedure
|
A procedural emboli is defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator.
|
During interventional procedure
|
Ankle-Brachial Index (ABI) at 30 Days
Time Frame: At 30 days
|
Ankle-Brachial Index (ABI) is the ratio of blood pressure in the lower legs to the blood pressure in the arms. It is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm. ABI < 0.95 indicates arterial disease; ABI between 0.95 and 1.3 is considered normal (free from significant peripheral artery disease); ABI > 1.3 is abnormal, and suggests calcification of the artery walls and incompressible vessels, indicating severe peripheral vascular disease. |
At 30 days
|
Rutherford Classification at 30 Days Post-procedure
Time Frame: At 30 days
|
Rutherford Classification is a commonly used clinical means for describing the degree of peripheral artery disease.
Rutherford Classifications range from Class 0: Asymptomatic, to Class 6: Major Tissue Loss.
A lower score is less severe disease and a higher score is more severe disease progression.
|
At 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: John B Simpson, MD, Avinger, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- P 0218
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherectomy in Diseased Lower Extremity Arteries
-
T.C. ORDU ÜNİVERSİTESİCompletedThis Study Was Focused on Selective Spinal Anesthesia for Lower Extremity Surgery in Order to Achieve Early Mobilization and to Shorten Hospital StayTurkey
-
Istanbul University-CerrahpasaTugtepe Pediatric Urology ClinicCompletedLower Urinary Tract Symptoms | Muscle Weakness Condition | Lower Extremity Problem | Posture Disorders in Children | Urinary Incontinence in ChildrenTurkey
-
Macrocure Ltd.ICON plc; Amarex Clinical Research; ARANZ MedicalCompletedLower Extremity Chronic Ulcers in DiabeticsUnited States, Israel, Canada
-
Assistance Publique Hopitaux De MarseilleUnknownEquinus Foot Deformity in Children With Cerebral PalsyFrance
-
Odense University HospitalOdense Patient Data Explorative NetworkRecruitingToe Joint Deformity | Clubfoot | Flatfoot | Trigger Finger | Syndactyly | Hand Deformities, Congenital | Tarsal Coalition | Congenital Talipes Equinovarus | Valgus Foot Deformity | Club Foot | Polydactyly Toe | Thumb Hypoplasia | Polydactyly; Fingers | Osteomyelitis of Hindfoot | Osteomyelitis of Midfoot | Congenital Talipes... and other conditionsDenmark
Clinical Trials on Wolverine System to perform atherectomy
-
University Hospital, GhentFlanders CareCompleted
-
AtheroMed, IncCompletedPeripheral Vascular DiseaseUnited States, Germany
-
Rex MedicalSyntactxCompletedPeripheral Artery DiseaseUnited States
-
Columbia UniversityCompletedCoronary Artery Disease (CAD)United States
-
McGill University Health Centre/Research Institute...UnknownNoncardiac Surgery | Risk Assessment | Postoperative Myocardial Infarction | Postoperative DeathCanada
-
University of California, San FranciscoCentre de Recherche en Sante de Nouna, Burkina FasoRecruitingSevere Acute MalnutritionBurkina Faso
-
Terumo Medical CorporationRecruiting
-
Boston Scientific CorporationCompletedPeripheral Arterial DiseaseJapan
-
Boston Scientific CorporationCompletedPeripheral Arterial DiseaseJapan
-
Boston Scientific CorporationCompleted